← Issue №17/ week of Oct 25, 2026/ the whole section, in full

Pancreas/Biliary, in full.

All 6 Pancreas/Biliary papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 6, in full

most clinically useful first
Pancreas/Biliary retrospective · n=276 · Oct 23, 2026 · J Clin Gastro · IF 2.9

Metabolic Syndrome Is Associated With Worsened Clinical Outcomes in Individuals With Necrotizing Pancreatitis.

Epidemiologyacute pancreatitisepidemiologybiomarker
Clinical takeawayCount metabolic syndrome as a risk marker when triaging necrotizing pancreatitis; this single-centre retrospective cohort does not test whether closer monitoring changes outcomes.
What it foundMetS in NP patients increased ICU admission (38.3% vs 17.2%), sepsis (27.5% vs 15.6%), organ failure (respiratory 31.2% vs 18%, renal 35.7% vs 21.3%), mortality (17.5% vs 8.2%), and IPN (39.6% vs 23.0%).
ContextConfirms prior evidence linking MetS to worse outcomes in acute pancreatitis, specifically extending findings to NP and IPN in a cohort of 276 patients admitted with NP at a single tertiary center.
Refinessuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
AbiMansour JP … Chandrasekhara V · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Pancreas/Biliary review · Oct 21, 2026 · Clin Gastro Hep · IF 16.2

Redefining Cholangiocarcinoma Management: Breakthroughs and Their Clinical Implications for Clinical Practice.

New evidencecholangiocarcinomabiomarkertranslationalguideline
Clinical takeawayMolecular profiling identifies candidates for biomarker-driven therapy, and immunotherapy has been integrated into first-line treatment; early detection and risk stratification remain the main gaps.
What it foundRecent advancements in imaging and next-generation sequencing (NGS) have improved diagnostic accuracy and identified actionable molecular alterations (e.g., FGFR2 fusions, IDH1 mutations) in cholangiocarcinoma.
ContextThis review highlights advancements in precision medicine for cholangiocarcinoma, particularly in unresectable or metastatic cases, emphasizing the role of molecular profiling and immunotherapy.
Emergingsuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Kodali S … Ghobrial RM · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Pancreas/Biliary rct · n=144 · Oct 23, 2026 · Nature Medicine · IF 52.5

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.

New evidencepancreatic cancerbiomarkertranslationalbasic science
Clinical takeawayNo clinical action yet: a phase 2 trial with promising but non-significant primary endpoint results. Await phase 3 confirmation before considering camupepimut in KRAS-mutated PDAC.
What it foundCamupepimut showed a numerical DFS advantage at 6 months compared to standard-of-care/observation (75.7% vs 61.7%; HR 0.55, P=0.0557) and improved DFS in ctDNA-negative patients (HR 0.51, P=0.0280) and those without prior radiation (HR 0.59, P=0.0221). Safety was similar to observation, with grade ≥3 adverse events in 10.4% versus 14.6%.
ContextChallenges current practice by suggesting a potential role for camupepimut in stage I-III KRAS-mutated PDAC without recurrence within 6 months of standard therapy, particularly in ctDNA-negative patients and those without prior radiation, though primary endpoint was not met.
Emergingsuggested applicable standard· National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma, Version 2.2025, verified directly against the metastatic first-line algorithm (PANC-10) and Principles of Systemic Therapy (PANC-F, 6 of 13), footnote y: "Good PS is defined as ECOG 0-1 ... and intermediate PS is defined as ECOG 2"; peer-reviewed publication of this guideline series with a resolving identifier: Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439-457.

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Evaluate suspected pancreatic adenocarcinoma with a dedicated pancreatic-protocol (multiphasic, contrast-enhanced) CT of the abdomen as the preferred imaging for diagnosis and staging (MRI/MRCP is an acceptable alternative); PET/CT may be added after, never as a substitute for, protocol CT/MRI in higher-risk situations. Obtain tissue confirmation, preferably by EUS-guided FNA/FNB with core biopsy where feasible; biopsy is generally required before neoadjuvant or palliative therapy, whereas patients with clearly resectable disease may proceed to surgery without preoperative biopsy. Measure baseline CA 19-9 (interpret after biliary decompression / with normal bilirubin; it can be falsely low in Lewis-antigen-negative patients and falsely elevated with cholestasis). Offer GERMLINE testing for inherited susceptibility to EVERY patient with confirmed pancreatic adenocarcinoma regardless of family history, using a comprehensive multi-gene panel; separately, for patients with locally advanced or metastatic disease who are candidates for anti-cancer therapy, obtain TUMOR/SOMATIC molecular profiling (broad NGS; RNA-based assays improve fusion detection; cell-free/liquid biopsy if tissue is insufficient). Assign resectability, resectable, borderline resectable, locally advanced (unresectable), or metastatic, by multidisciplinary review, ideally at a high-volume center. RESECTABLE disease: upfront resection (pancreaticoduodenectomy for head/uncinate; distal pancreatectomy ± splenectomy for body/tail) followed by adjuvant therapy, or neoadjuvant therapy in selected high-risk patients; preferred adjuvant regimen is modified FOLFIRINOX in patients able to tolerate it, ideally begun within 12 weeks of surgery, for a total of ~6 months of perioperative systemic therapy. BORDERLINE RESECTABLE and LOCALLY ADVANCED disease: neoadjuvant systemic therapy, with or without subsequent chemoradiation/RT, then restaging and reassessment for resection. METASTATIC disease by performance status: good PS (ECOG 0-1, adequate organ function), first-line FOLFIRINOX/modified FOLFIRINOX, NALIRIFOX, or gemcitabine + nab-paclitaxel, with clinical trial preferred; after ~4-6 months without progression, transition to a maintenance strategy (including olaparib for germline BRCA1/2 carriers who have NOT progressed on first-line platinum-based therapy), a clinical trial, or a treatment break; intermediate PS (ECOG 2), clinical trial preferred, otherwise less-intensive first-line therapy (preferred gemcitabine + nab-paclitaxel [category 1], or single-agent gemcitabine or capecitabine, or FOLFOX/FOLFIRI/CapeOx), since the intensive triplets (FOLFIRINOX/modified FOLFIRINOX and NALIRIFOX) are limited to ECOG 0-1 and are generally not appropriate at ECOG 2, with the same maintenance-versus-progression reassessment applied after ~4-6 months without progression; poor PS (ECOG 3-4), palliative/best supportive care, with single-agent chemotherapy or a biomarker-directed agent only if clinically appropriate. Treat by molecular target wherever an actionable alteration is present, across lines: pembrolizumab (or dostarlimab) for MSI-H/dMMR and pembrolizumab for TMB-H, olaparib for germline BRCA1/2 (maintenance after platinum), larotrectinib/entrectinib for NTRK fusions, selpercatinib for RET fusions, dabrafenib + trametinib for BRAF V600E, erdafitinib for FGFR2 alterations, fam-trastuzumab deruxtecan for HER2-positive disease, zenocutuzumab for NRG1 fusion-positive disease, and (in recent NCCN versions) KRAS G12C inhibitors (adagrasib/sotorasib), several of these after prior systemic therapy. Integrate supportive care throughout: relieve obstructive jaundice with an endoscopic self-expanding metal stent in non-operative or neoadjuvant pathways, but do NOT perform routine preoperative biliary drainage before planned upfront resection; treat exocrine insufficiency with pancreatic enzyme replacement titrated to symptoms (common starting dose ~40,000-50,000 units of lipase with main meals, roughly half with snacks, increased as needed); manage refractory pain with celiac plexus neurolysis or palliative RT; relieve gastric outlet obstruction with surgical or EUS-guided gastrojejunostomy (or enteral stenting); and provide VTE prophylaxis, nutritional support, and early palliative care.

National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma, Version 2.2025, verified directly against the metastatic first-line algorithm (PANC-10) and Principles of Systemic Therapy (PANC-F, 6 of 13), footnote y: "Good PS is defined as ECOG 0-1 ... and intermediate PS is defined as ECOG 2"; peer-reviewed publication of this guideline series with a resolving identifier: Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439-457. · reviewed 2026-07-23 ↗
George B … O'Reilly EM · Nature Medicine · IF 52.5 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=110,225 · Oct 22, 2026 · Pancreas · IF 1.9

Venous Thromboembolism in Acute Necrotizing Pancreatitis Is Associated With Worse Outcomes, With Subtype-Specific Patterns: A Nationwide Analysis, 2016-2022.

New evidenceepidemiologyacute pancreatitis
Clinical takeawayAn administrative-data association: VTE subtypes carried distinct complication patterns (PVT with mesenteric ischemia, SVT with gastric varices); the authors call for prospective study of phenotype-specific anticoagulation, so no change to anticoagulation follows yet.
What it foundANP with VTE had higher in-hospital mortality (aOR 1.89), longer length of stay (adjusted mean difference 10.7 days), and higher hospitalization charges (adjusted mean difference $151,685).
ContextConfirms and quantifies the adverse impact of VTE in adults hospitalized with ANP, with subtype-specific patterns (DVT and PVT linked to higher mortality, PVT to mesenteric ischemia, SVT to gastric varices).
Emergingsuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
Kohli S … Chawla S · Pancreas · IF 1.9 · PubMed ↗Permalink
Pancreas/Biliary prospective cohort · n=1,927 · Oct 22, 2026 · Clin Transl Gastro · IF 3.4

Psychometric Validation of PROMIS Measures in Acute and Chronic Pancreatitis.

New evidenceacute pancreatitischronic pancreatitis
Clinical takeawayConsider using PROMIS-29, PROMIS-Global Health, and PROMIS Pain Quality scales for consistent and reliable assessment of symptom burden and QoL in AP/CP patients in both clinical research and patient care.
What it foundPROMIS measures exceeded all psychometric benchmarks tested, including univariate construct validity, known-groups validity, convergent validity, reliability, structural validity, and population invariance across age, sex, race, and diagnostic subgroups in AP/CP patients.
ContextConfirms the suitability of PROMIS measures for AP/CP, addressing a gap in robust psychometric evidence for existing instruments in this population.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Askew RL … Consortium for the Study of Chronic Pancreatitis, Diabetes, Pancreatic Cancer (CPDPC) · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
Pancreas/Biliary review · Oct 20, 2026 · Pancreatology · IF 3.0

Metabolic dysfunctions in pancreatic ductal adenocarcinoma: Pathogenic mechanisms and therapeutic implications.

Basic sciencebasic sciencetranslationalpancreatic cancerbiomarker
Clinical takeawayNo clinical action yet: preclinical findings in PDAC models suggest potential for metabolic modulators, but human evidence is inconclusive.
What it foundStatins and metformin show antitumor effects in preclinical PDAC models, but clinical trial data on survival benefits remain inconsistent.
ContextChallenges current understanding of PDAC treatment by highlighting metabolic dysfunctions as drivers of chemoresistance and proposing repurposed metabolic modulators.
Emergingsuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.

American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149 · reviewed 2026-07-23 ↗
Rodrigues R … Xavier CPR · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
← Back to issue №17 Every section of this issue is one click away, at the top of this page. Follow Pancreas/Biliary by RSS